Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells (Q36094977)

12 August 2017

Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells (English)

1 reference

12 August 2017

1 reference

acute myeloid leukemia

1 reference

childhood acute myeloid leukemia

inferred from title

1 reference

Chengzhi Xie

1

1 reference

12 August 2017

Holly Edwards

2

1 reference

12 August 2017

Salvatore B Lograsso

3

1 reference

12 August 2017

Steven A Buck

4

1 reference

12 August 2017

Larry H Matherly

5

1 reference

12 August 2017

Jeffrey W Taub

6

1 reference

12 August 2017

Yubin Ge

7

1 reference

12 August 2017

5 April 2012

1 reference

12 August 2017

Pediatric Blood Cancer

1 reference

12 August 2017

59

1 reference

12 August 2017

7

1 reference

12 August 2017

1245-1251

1 reference

Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Histone deacetylase inhibitors: a new perspective for the treatment of leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Cytogenetics of pediatric acute myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Pediatric acute myeloid leukemia: towards high-quality cure of all patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Clofarabine: past, present, and future

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Targeting transcription factors in acute leukemia in children

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Anticancer activities of histone deacetylase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Clinical development of histone deacetylase inhibitors as anticancer agents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Drug synergism: its detection and applications

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396758

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

2 October 2017

1 reference

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

21 January 2018

1 reference

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22488775

12 December 2020

inferred from PubMed ID database lookup

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22488775

12 December 2020

inferred from PubMed ID database lookup

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22488775

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/PBC.24152

1 reference

12 August 2017

1 reference

12 August 2017

1 reference